For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total net revenue | - | 164,070 | ||
| Total revenue | 263,502 | - | ||
| Cost of sales | 173,184 | 123,995 | ||
| Research and development | 300,270 | 282,336 | ||
| Selling, general, and administrative | 152,322 | 153,017 | ||
| Depreciation and amortization | 35,939 | - | ||
| Restructuring charges | 5,143 | - | ||
| Total costs and expenses | 666,858 | 559,348 | ||
| Loss from operations | -403,356 | -395,278 | ||
| Interest and other income, net | 10,307 | 20,273 | ||
| Net loss before income taxes | -393,049 | -375,005 | ||
| Income tax (expense) benefit | -2,071 | -2,828 | ||
| Net loss | -390,978 | -372,177 | ||
| Basic EPS | -1.09 | -1.28 | ||
| Diluted EPS | -1.09 | -1.28 | ||
| Basic Average Shares | 357,345 | 289,877 | ||
| Diluted Average Shares | 357,345 | 289,877 | ||
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)